BioCardia (NASDAQ:BCDA – Get Rating) had its price objective dropped by equities researchers at Maxim Group to $4.00 in a note issued to investors on Thursday, Stock Target Advisor reports. Maxim Group’s target price points to a potential upside of 151.57% from the stock’s previous close.
Other analysts have also issued research reports about the stock. Brookline Capital Management restated a “buy” rating on shares of BioCardia in a research report on Thursday, February 3rd. Zacks Investment Research upgraded shares of BioCardia from a “sell” rating to a “hold” rating in a report on Monday, April 11th.
BioCardia stock traded up $0.04 during midday trading on Thursday, reaching $1.59. 1,348 shares of the company’s stock were exchanged, compared to its average volume of 1,278,841. The firm has a market cap of $27.74 million, a price-to-earnings ratio of -2.09 and a beta of 1.40. BioCardia has a 52 week low of $1.10 and a 52 week high of $5.10. The stock’s 50-day simple moving average is $1.75 and its 200 day simple moving average is $1.94.
A number of hedge funds and other institutional investors have recently bought and sold shares of BCDA. Renaissance Technologies LLC bought a new position in BioCardia in the 1st quarter valued at about $28,000. Millennium Management LLC bought a new stake in BioCardia in the 3rd quarter worth about $31,000. Dimensional Fund Advisors LP purchased a new stake in BioCardia in the 1st quarter valued at about $57,000. Commonwealth Equity Services LLC lifted its position in shares of BioCardia by 156.5% during the 4th quarter. Commonwealth Equity Services LLC now owns 42,307 shares of the company’s stock worth $82,000 after buying an additional 25,815 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of BioCardia in the fourth quarter valued at approximately $109,000. 15.40% of the stock is owned by institutional investors and hedge funds.
About BioCardia (Get Rating)
BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease.
- Get a free copy of the StockNews.com research report on BioCardia (BCDA)
- Genesco Pops On Earnings But Don’t Expect A Rally
- The Insiders Are Selling Movado Group, But You Shouldn’t
- Beware The Rebound In Retail Stocks
- It’s A Good Time To Own Ralph Lauren (NYSE: RL)
- Block, Inc: Correcting for Negative Earnings
Want More Great Investing Ideas?
- Bear Market Game Plan!
- The 10 Best Stocks to Own in 2022
- 7 Stocks to Buy and Hold Forever
- 3 Stocks to DOUBLE This Year
Receive News & Ratings for BioCardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCardia and related companies with MarketBeat.com's FREE daily email newsletter.